Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 53

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 53
---
 issued to our related parties:

| Purchasers(1)                                           |     | Shares of Series C 
 Preferred Stock    |           |     | Total Purchase Price |            |
|:--------------------------------------------------------|:----|:-------------------|----------:|:----|:---------------------|-----------:|
| Entities affiliated with Atlas Venture(2)               |     |                    | 1,153,967 |     | $                    | 11,265,026 |
| OrbiMed Private Investments VIII, LP(3)                 |     |                    | 2,048,760 |     | $                    | 19,999,995 |
| Entities affiliated with RA Capital(4)                  |     |                    | 5,456,093 |     | $                    | 53,262,380 |
| Sionna Aggregator, LP(5)                                |     |                    | 2,817,045 |     | $                    | 27,499,993 |
| Entities affiliated with TPG Growth(6)                  |     |                    | 1,765,541 |     | $                    | 17,235,211 |
| Entities affiliated with Viking Global Opportunities(7) |     |                    | 2,560,950 |     | $                    | 24,999,994 |

| (1) | Additional details regarding these stockholders and their equity holdings are included in this proxy statement under the section “Security Ownership of Certain Beneficial Owners and Management.” |

| (2) | Consists of (i) 61,463 shares of Series C preferred stock held by Atlas Venture Fund XI, L.P. and (ii) 1,092,504 shares of Series C preferred stock held by Atlas Venture Opportunity Fund II, L.P. Entities affiliated with Atlas Ventures beneficially own more than 5% of our outstanding capital stock. Bruce Booth, D.Phil., a member of our board of directors, is a general partner at Atlas Ventures. |

| (3) | OrbiMed beneficially owns more than 5% of our outstanding capital stock. Peter A. Thompson, M.D., a member of our board of directors, is a member at OrbiMed. |

| (4) | Consists of (i) 4,364,874 shares of Series C preferred stock held by RA Capital Healthcare Fund, L.P. and (ii) 1,091,219 shares of Series C preferred stock held by RA Capital Nexus Fund, L.P